Connect with us
  • Elysium


European Parkinson’s treatment launch – AbbVie



Pharma firm AbbVie has announced the launch in the European Union of Parkinson’s treatment Produodopa.

The product is use for the treatment of advanced Parkinson's with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement), and when available combinations of Parkinson's medicinal products have not given satisfactory results.

PRODUODOPA is the first subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations in people living with advanced Parkinson's disease whose symptoms are inadequately controlled by other therapies.

Read this and more exclusive content every day as an NR Times online subscriber. Just £2.99 a month, cancel anytime.

Login Join Now